Hamid Omid, Goldenberg Gary
J Drugs Dermatol. 2013 Nov;12(11):1246-52; quiz 1253-4.
Basal cell carcinoma (BCC) is a common skin cancer and its incidence is on the rise worldwide. Clinical presentation and histologic examination are used for diagnosis and to stratify BCCs as either low- or high-risk for recurrence or development of advanced disease. A number of surgical and nonsurgical options are available for BCC. BCC is most often managed with a surgical approach, but not all tumors and patients are suitable for surgery. Vismodegib is a recently approved first-in-class hedgehog pathway inhibitor that has expanded options for patients who have locally advanced or metastatic BCC.
基底细胞癌（BCC）是一种常见的皮肤癌，其发病率在全球范围内呈上升趋势。临床表现和组织学检查用于诊断以及将基底细胞癌分为复发或进展为晚期疾病的低风险或高风险类型。基底细胞癌有多种手术和非手术治疗选择。基底细胞癌最常采用手术方法治疗，但并非所有肿瘤和患者都适合手术。维莫德吉是一种最近获批的一流的刺猬信号通路抑制剂，为局部晚期或转移性基底细胞癌患者增加了治疗选择。
